|
|
| | AC-GLY-ASP-TYR-SER-HIS-CYS-SER-PRO-LEU-ARG-TYR-TYR-PRO-TRP-TRP-LYS-CYS-THR-TYR-PRO-ASP-PRO-GLU-GLY-GLY-GLY-NH2, (DISULFIDE BOND) TRIFLUOROACETATE Basic information |
| Product Name: | AC-GLY-ASP-TYR-SER-HIS-CYS-SER-PRO-LEU-ARG-TYR-TYR-PRO-TRP-TRP-LYS-CYS-THR-TYR-PRO-ASP-PRO-GLU-GLY-GLY-GLY-NH2, (DISULFIDE BOND) TRIFLUOROACETATE | | Synonyms: | AC-GLY-ASP-TYR-SER-HIS-CYS-SER-PRO-LEU-ARG-TYR-TYR-PRO-TRP-TRP-LYS-CYS-THR-TYR-PRO-ASP-PRO-GLU-GLY-GLY-GLY-NH2, (DISULFIDE BOND) TRIFLUOROACETATE;DX-600;Ac-Gly-Asp-Tyr-Ser-His-Cys-Ser-Pro-Leu-Arg-Tyr-Tyr-Pro-Trp-Trp-Lys-Cys-Thr-Tyr-Pro-Asp-Pro-Glu-Gly-Gly-Gly-NH2 trifluoroacetate salt (Disulfide bond);Ac-Gly-Asp-Tyr-Ser-His-Cys-Ser-Pro-Leu-Arg-Tyr-Tyr-Pro-Trp-Trp-Lys-Cys-Thr-Tyr-Pro-Asp-Pro-Glu-Gly-Gly-Gly-NH trifluoroacetate salt (Disulfide bond);Ac-Gly-Asp-Tyr-Ser-His-Cys-Ser-Pro-Leu-Arg-Tyr-Tyr-Pro-Trp-Trp-Lys-Cys-Thr-Tyr-Pro-Asp-Pro-Glu-Gly-Gly-Gly-NH2 (Disulfide bond);Glycinamide, N-acetylglycyl-L-α-aspartyl-L-tyrosyl-L-seryl-L-histidyl-L-cysteinyl-L-seryl-L-prolyl-L-leucyl-L-arginyl-L-tyrosyl-L-tyrosyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-lysyl-L-cysteinyl-L-threonyl-L-tyrosyl-L-prolyl-L-α-aspartyl-L-prolyl-L-α-glutamylglycylglycyl-, cyclic (6→17)-disulfide;Angiotensin I Converting Enzyme 2 (ACE-2) Inhibitor, DX 600 - 0.1 mg | | CAS: | 478188-26-0 | | MF: | C141H185N35O40S2 | | MW: | 3074.32 | | EINECS: | | | Product Categories: | | | Mol File: | 478188-26-0.mol |  |
| | AC-GLY-ASP-TYR-SER-HIS-CYS-SER-PRO-LEU-ARG-TYR-TYR-PRO-TRP-TRP-LYS-CYS-THR-TYR-PRO-ASP-PRO-GLU-GLY-GLY-GLY-NH2, (DISULFIDE BOND) TRIFLUOROACETATE Chemical Properties |
| density | 1.57±0.1 g/cm3(Predicted) | | form | Solid | | color | White to off-white |
| | AC-GLY-ASP-TYR-SER-HIS-CYS-SER-PRO-LEU-ARG-TYR-TYR-PRO-TRP-TRP-LYS-CYS-THR-TYR-PRO-ASP-PRO-GLU-GLY-GLY-GLY-NH2, (DISULFIDE BOND) TRIFLUOROACETATE Usage And Synthesis |
| Uses | DX600 is a selective ACE2 specific inhibitor (KD: 1.3 nM), and does not cross-react with ACE. DX600 exacerbates diabetes-induced cardiovascular dysfunction and the increase in cardiac and renal NOX activity[1][2][3]. | | in vivo | DX600 (5 μg/kg/day, i.p., daily for 4 weeks) exacerbates diabetes-induced cardiovascular dysfunction in Streptozotocin (HY-13753)-treated diabetes rats[2].
DX600 (0.1 μmol/L/kg, i.v ) increases thrombus weight by 30% in thrombosis model in rats[5].
| Animal Model: | STZ-treated diabetes rats[2] | | Dosage: | 5 μg/kg/day | | Administration: | i.p., daily for 4 weeks | | Result: | Increased cardiac and renal NOX activity. |
| | References | [1] Liao K, et al. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2).J Immunol Methods.?2013 Mar 29;389(1-2):52-60. DOI:10.1016/j.jim.2012.12.010
[2] Yousif MH, et al. Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol Res. 2012 Sep;66(3):269-75. DOI:10.1016/j.phrs.2012.05.001
[3] Svilenov HL, et al. Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. Commun Biol. 2023 Apr 8;6(1):386. DOI:10.1038/s42003-023-04762-w
[4] Joshi S, et al. Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. Eur J Pharmacol. 2016 Mar 5;774:25-33. DOI:10.1016/j.ejphar.2016.01.007
[5] Fraga-Silva RA, et al. ACE2 activation promotes antithrombotic activity. Mol Med. 2010 May-Jun;16(5-6):210-5. DOI:10.2119/molmed.2009.00160 |
| | AC-GLY-ASP-TYR-SER-HIS-CYS-SER-PRO-LEU-ARG-TYR-TYR-PRO-TRP-TRP-LYS-CYS-THR-TYR-PRO-ASP-PRO-GLU-GLY-GLY-GLY-NH2, (DISULFIDE BOND) TRIFLUOROACETATE Preparation Products And Raw materials |
|